Unstable angina
Conditions
Interventions
Placebo group:Placebo
Sponsors
Xian Wang
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed UA patients; 2. Aged 18 to 80 years; 3. No gender restriction; 4. According to the requirements of GCP, the subjects will sign the informed consent form knowingly and voluntarily.
Exclusion criteria
Exclusion criteria: 1. Patients with diagnosis of AMI, stroke or undergone PCI or coronary artery bypass grafting (CABG) within 1 month prior to enrollment; 2. Patients with coexistent severe heart failure (NYHA, Class IV) and severe arrhythmia (atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, sinus bradycardia (heart rate = 160mmHg or diastolic blood pressure >= 100mmHg); 5. With the terminal phase cachexia of malignant tumors; 6. With high bleeding risk,such as history of hemorrage of vital organs (brain or upper gastrointestinal tract) within 6 months, low platelet counts, abnormal coagulation function, recent active hemorrhage,etc.; 7. Patients with bleeding tendency within 1 month after operation; 8. Women who are under breastfeeding, pregnant or preparing for pregnancy; 9. With poor compliance; 10. Patients with known or suspected allergy to the test drug or allergic constitution; 11. Patients who participate in any other clinical study or take any of its investigational drugs within the last three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| major adverse cardiac events; | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-6;Myocardial nuclides;TCM syndrome;MMP-9;Seattle angina scale score;wall motion score index;electrocardiogram;C-reactive protein; | — |
Countries
China
Contacts
Public ContactXian Wang
Dongzhimen Hospital of Beijing University of traditional Chinese Medicine
Outcome results
None listed